Alnylam reported initial Phase 1b data for brezosiran in Huntington’s disease on October 23. The company described the findings as positive, with deep and durable lowering of huntingtin. The information provided does not include trial results, participant numbers, safety findings, or details on the size and duration of the effect.
Investor takeaway: This is an early clinical data point for brezosiran. The available facts do not establish its safety, clinical benefit, or prospects for further development.
Alnylam shares closed at US$224.03
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$29.98B
P/E
37.8x
52W high
$484.61
52W low
$197.81
1W change
-3.36%
Beta
0.27
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Oct 26, 2026
Wall Street analysts forecast ALNY stock price to rise 64.2% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
C$367.78
+64.2% Upside
Previously C$368.71 on Oct 19, 2026
Current Price
C$224.03
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
40.4%
Annualized
90-Day Vol
70.8%
Annualized
Trend (90d)
+36.3%
Annualized drift
90d Mean
C$255.04
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$233.92 | C$203.51 – C$268.88 |
| 60 trading days | C$244.25 | C$200.58 – C$297.43 |
| 90 trading days | C$255.04 | C$200.37 – C$324.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
The supplied quote data show a 1.43% one-day decline. Reported volume was 90 shares, compared with a 20-day average of 1,304,283. The available facts do not show that the announcement caused the share-price move.
Bull case
Alnylam described the initial Phase 1b findings as positive and reported deep, durable lowering of huntingtin, a biological measure highlighted in the announcement.
Bear case
The available information does not include detailed efficacy or safety results, the trial design, participant numbers, or evidence that huntingtin lowering leads to clinical benefit.
What happened: initial Phase 1b data for brezosiran
Alnylam’s October 23 announcement covers brezosiran, also known as ALN-HTT02, for Huntington’s disease. The company called the initial Phase 1b data positive and said they showed deep and durable huntingtin lowering.
That is the extent of the clinical detail provided. The information does not include the study design, number of participants, doses, specific measurements, safety results, or changes in patients’ symptoms. You can follow ALNY.US on the Alnylam stock page, but the announcement alone does not show whether the findings will lead to clinical benefit or further development milestones.
Advertisement
What the numbers show: shares and reported volume
Alnylam’s last close was US$224.03. The supplied figures show the shares down 1.43% over one day, 3.36% over one week, 9.12% over one month, and 44.02% year to date.
Reported volume was 90 shares, compared with a 20-day average of 1,304,283, or 0.81 times that average. The information does not specify when or in what context the volume was recorded, so it does not establish a market reaction to the announcement. The close was also below the supplied 50-day average of US$239.05 and 200-day average of US$289.88. These figures describe trading, not the clinical significance of brezosiran’s early data.
What to watch next: details not yet provided
Further trial results could clarify the size and durability of huntingtin lowering, safety, study design, and any clinical measures. None of those details is included in the information provided. It also does not say when Alnylam may release more data or outline a development timeline.
Investors can check the Alnylam stock page for listed-share information. The clinical announcement and the supplied price and volume figures should be considered separately.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
